These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 26435213

  • 1. Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma.
    Sauer S.
    Trends Pharmacol Sci; 2015 Oct; 36(10):688-704. PubMed ID: 26435213
    [Abstract] [Full Text] [Related]

  • 2. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.
    Li Y, Wang Z, Furukawa N, Escaron P, Weiszmann J, Lee G, Lindstrom M, Liu J, Liu X, Xu H, Plotnikova O, Prasad V, Walker N, Learned RM, Chen JL.
    J Biol Chem; 2008 Apr 04; 283(14):9168-76. PubMed ID: 18263587
    [Abstract] [Full Text] [Related]

  • 3. Peroxisome Proliferator-Activated Receptor γ (PPARγ) and Ligand Choreography: Newcomers Take the Stage.
    Garcia-Vallvé S, Guasch L, Tomas-Hernández S, del Bas JM, Ollendorff V, Arola L, Pujadas G, Mulero M.
    J Med Chem; 2015 Jul 23; 58(14):5381-94. PubMed ID: 25734377
    [Abstract] [Full Text] [Related]

  • 4. Structural basis for differential activities of enantiomeric PPARγ agonists: Binding of S35 to the alternate site.
    Jang JY, Koh M, Bae H, An DR, Im HN, Kim HS, Yoon JY, Yoon HJ, Han BW, Park SB, Suh SW.
    Biochim Biophys Acta Proteins Proteom; 2017 Jun 23; 1865(6):674-681. PubMed ID: 28342850
    [Abstract] [Full Text] [Related]

  • 5. Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ.
    Jang JY, Bae H, Lee YJ, Choi YI, Kim HJ, Park SB, Suh SW, Kim SW, Han BW.
    Sci Rep; 2018 Jan 08; 8(1):31. PubMed ID: 29311579
    [Abstract] [Full Text] [Related]

  • 6. Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions.
    Schopfer FJ, Cole MP, Groeger AL, Chen CS, Khoo NK, Woodcock SR, Golin-Bisello F, Motanya UN, Li Y, Zhang J, Garcia-Barrio MT, Rudolph TK, Rudolph V, Bonacci G, Baker PR, Xu HE, Batthyany CI, Chen YE, Hallis TM, Freeman BA.
    J Biol Chem; 2010 Apr 16; 285(16):12321-33. PubMed ID: 20097754
    [Abstract] [Full Text] [Related]

  • 7. A review on the development in the field of NIDDM based thiazolidinedione PPARγ agonists.
    Banerjee PS, Samanta S.
    Mini Rev Med Chem; 2013 Apr 01; 13(5):706-12. PubMed ID: 22512587
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Peroxisome proliferator activated receptor gamma and oxidized docosahexaenoic acids as new class of ligand.
    Itoh T, Yamamoto K.
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun 01; 377(4-6):541-7. PubMed ID: 18193404
    [Abstract] [Full Text] [Related]

  • 11. A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity.
    Choi SS, Kim ES, Koh M, Lee SJ, Lim D, Yang YR, Jang HJ, Seo KA, Min SH, Lee IH, Park SB, Suh PG, Choi JH.
    J Biol Chem; 2014 Sep 19; 289(38):26618-26629. PubMed ID: 25100724
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain.
    Amato AA, Rajagopalan S, Lin JZ, Carvalho BM, Figueira AC, Lu J, Ayers SD, Mottin M, Silveira RL, Souza PC, Mourão RH, Saad MJ, Togashi M, Simeoni LA, Abdalla DS, Skaf MS, Polikparpov I, Lima MC, Galdino SL, Brennan RG, Baxter JD, Pitta IR, Webb P, Phillips KJ, Neves FA.
    J Biol Chem; 2012 Aug 10; 287(33):28169-79. PubMed ID: 22584573
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Structural basis for the inhibitory effects of a novel reversible covalent ligand on PPARγ phosphorylation.
    Jang JY, Kim H, Kim HJ, Suh SW, Park SB, Han BW.
    Sci Rep; 2019 Aug 01; 9(1):11168. PubMed ID: 31371757
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.